With technology licensed from Stanford, the partners hope to land a preventive drug into clinical trials against malaria by early 2023.
Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria. MAM01/ATRC-501 is a monoclonal antibody entering preclinical development. Under the agreement, Gates MRI will lead the development of MAM01/ATRC-501 and receive commercial rights in GAVI-eligible countries. Atreca will retain commercial rights in the U.S., Europe, and parts of Asia. MAM01/ATRC-501 is an engineered version of a hum
SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute (the “Institute” or “Gates MRI”) to develop MAM01/ATRC-501, a novel monoclonal antibody entering precl